{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:20:27Z","timestamp":1761823227018},"reference-count":90,"publisher":"Hindawi Limited","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2191,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1111\/j.1529-8019.2009.01258.x","type":"journal-article","created":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T17:51:23Z","timestamp":1251827483000},"page":"418-430","source":"Crossref","is-referenced-by-count":44,"title":["Is there truly a risk of lymphoma from biologic therapies?"],"prefix":"10.1155","volume":"22","author":[{"given":"Erica","family":"Dommasch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","reference":[{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB1","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaad.2004.04.014","article-title":"Determinants of quality of life in patients with psoriasis: a study from the US population","volume":"51","author":"Gelfand","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB2","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB3","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB4","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/archderm.143.12.1493","article-title":"The risk of mortality in patients with psoriasis: results from a population-based study","volume":"143","author":"Gelfand","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jaad.2008.09.022","article-title":"The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004","volume":"60","author":"Kurd","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mjd.2002.120568","article-title":"The immunologic basis for the treatment of psoriasis with new biologic agents","volume":"46","author":"Krueger","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB7","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","article-title":"Psoriasis","volume":"352","author":"Schon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Gerhard","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB9","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1136\/jcp.2007.051953","article-title":"HIV infection and lymphoma","volume":"60","author":"Grogg","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB10","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.285.14.1880","article-title":"HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis","volume":"285","author":"Little","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-642-56352-2_8","article-title":"The role of immunosuppression in lymphoma","volume":"159","author":"Trofe","year":"2002","journal-title":"Recent Results Cancer Res"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.yadr.2008.09.006","article-title":"Update on the natural history and systemic treatment of psoriasis","volume":"24","author":"Richardson","year":"2008","journal-title":"Adv Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/1744666X.3.2.171","article-title":"Update on the epidemiology and systemic treatment of psoriasis","volume":"3","author":"Kurd","year":"2007","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB15","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jaad.2006.07.019","article-title":"Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2)","volume":"56","author":"Graves","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1111\/j.1529-8019.2009.01258.x-BIB16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaad.2008.11.898","article-title":"A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa","volume":"60","author":"Lee","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00001622-200009000-00002","article-title":"Epidemiology of lymphomas","volume":"12","author":"Baris","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB18","volume-title":"Cancer Statistics: 1999-2004 Incidence and Mortality Web-based Report","author":"U.S. Cancer Statistics Working Group","year":"2007"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB19","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1158\/1055-9965.EPI-06-0300","article-title":"Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk Factors, and lymphoma characteristics","volume":"15","author":"Smedby","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB20","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium","volume":"111","author":"Smedby","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB22","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/ard.2005.044784","article-title":"Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis","volume":"65","author":"Franklin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB24","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1002\/1097-0142(19851215)56:12<2914::AID-CNCR2820561232>3.0.CO;2-J","article-title":"Extraintestinal cancers in inflammatory bowel disease","volume":"56","author":"Greenstein","year":"1985","journal-title":"Cancer"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB25","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/cncr.2820690510","article-title":"Lymphoma in inflammatory bowel disease","volume":"69","author":"Greenstein","year":"1992","journal-title":"Cancer"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB26","volume-title":"Comprehensive dermatologic drug therapy","author":"Gelfand","year":"2007"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB27","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/j.1572-0241.2003.08682.x","article-title":"Acute leukemia after infliximab therapy","volume":"98","author":"Alca\u00edn","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3816\/CLM.2006.n.008","article-title":"Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy","volume":"6","author":"Berthelot","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB29","first-page":"646","article-title":"Case reports: efalizumab-associated lymphoproliferative disease","volume":"6","author":"Bommakanti","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2133.2005.06686.x","article-title":"Mycosis fungoides-associated follicular mucinosis under adalimumab","volume":"153","author":"Dalle","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB31","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2133.2006.07713.x","article-title":"Acute Sezary syndrome in a patient receiving infliximab for ankylosing spondylitis","volume":"156","author":"Dauendorffer","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5694\/j.1326-5377.2008.tb02124.x","article-title":"Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease","volume":"189","author":"Drini","year":"2008","journal-title":"Med J Aust"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2133.2008.08664.x","article-title":"Gastric MALT lymphoma in a patient receiving infliximab for psoriasis","volume":"159","author":"Girard","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1746-1596-3-13","article-title":"A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists","volume":"3","author":"Hurley","year":"2008","journal-title":"Diagn Pathol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/s10165-008-0053-0","article-title":"Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis","volume":"18","author":"Komatsuda","year":"2008","journal-title":"Mod Rheumatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB36","first-page":"100","article-title":"Crohn's disease associated lymphoma after treatment with infliximab","volume":"4","author":"Kong","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB37","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1046\/j.1365-2133.2003.05384.x","article-title":"CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab","volume":"149","author":"Mah\u00e9","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB38","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ajh.20926","article-title":"TNF-alpha inhibitor etanercept and hematologic malignancies: Report of a case and review of the literature","volume":"82","author":"Nair","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2230.2007.02683.x","article-title":"Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate","volume":"33","author":"Nakashima","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB40","first-page":"691","article-title":"Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization","volume":"91","author":"Quartuccio","year":"2006","journal-title":"Haematologica"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/jcp.2006.037556","article-title":"Plasmablastic lymphoma presenting as a paravertebral mass in a patient with Crohn's disease after immunosuppressive therapy","volume":"60","author":"Redmond","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB42","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/rheumatology\/41.10.1194","article-title":"Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab","volume":"41","author":"Roddy","year":"2002","journal-title":"Rheumatology"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB43","first-page":"6","article-title":"Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy. (CASE REPORTS) (Case study)","volume":"834","author":"Sanli","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaad.2005.02.043","article-title":"Transformed mycosis fungoides developing after treatment with alefacept","volume":"53","author":"Schmidt","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB45","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.cgh.2006.05.024","article-title":"Case report: Lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease","volume":"4","author":"Schwartz","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB46","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/ard.2004.026252","article-title":"Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment","volume":"64","author":"Thonhofer","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB47","first-page":"108","article-title":"Lymphoma development in a patient receiving anti-TNF therapy","volume":"88","author":"Ziakas","year":"2003","journal-title":"Haematologica"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB48","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jaad.2004.03.047","article-title":"Aggressive cutaneous T-cell lymphomas after TNFalpha blockade","volume":"51","author":"Adams","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB49","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease","volume":"44","author":"Mackey","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB51","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0016-5085(99)70294-5","article-title":"The relationship between infliximab treatment and lymphoma in Crohn's disease","volume":"117","author":"Bickston","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB52","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/gut.2008.163279","article-title":"Hepatosplenic T cell lymphoma in inflammatory bowel disease","volume":"57","author":"Shale","year":"2008","journal-title":"Gut"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB53","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1182\/blood.V88.11.4265.bloodjournal88114265","article-title":"Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin","volume":"88","author":"Cooke","year":"1996","journal-title":"Blood"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB54","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJM198103123041106","article-title":"Erythrophagocytic T gamma lymphoma: a clinicopathologic entity resembling malignant histiocytosis","volume":"304","author":"Kadin","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB55","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ibd.20169","article-title":"Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?","volume":"13","author":"Rosh","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB56","first-page":"810","article-title":"Reversible methotrexate associated lymphoproliferative disease evolving into Hodgkin's disease","volume":"27","author":"Mosely","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB57","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(84)90994-2","article-title":"Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy","volume":"1","author":"Starzl","year":"1984","journal-title":"Lancet"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB58","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ncprheum0761","article-title":"Safe adalimumab therapy for rheumatoid arthritis in a patient with pre-existing multiple myeloma","volume":"4","author":"Mielke","year":"2008","journal-title":"Nat Clin Pract Rheum"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB59","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/j.1365-2230.2008.02973.x","article-title":"Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma","volume":"34","author":"Chong","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB60","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/j.jaad.2006.05.074","article-title":"Patch-stage mycosis fungoides in remission after therapy with alefacept","volume":"58","author":"Green","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB61","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000095037","article-title":"A review of malignancies observed during efalizumab (Raptiva\u00ae) clinical trials for plaque psoriasis","volume":"213","author":"Leonardi","year":"2006","journal-title":"Dermatology"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB62","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archdermatol.2008.530","article-title":"Progression of undiagnosed cutaneous T-cell lymphoma during efalizumab therapy","volume":"145","author":"Hernandez","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB63","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archdermatol.2008.526","article-title":"Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept","volume":"145","author":"Lafaille","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB64","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB65","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB66","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB67","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB68","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/ard.2005.035311","article-title":"Risk of lymphoma in patients with RA treated with anti-TNF{alpha} agents","volume":"64","author":"Franklin","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB69","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB70","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1002\/art.22277","article-title":"Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB71","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00838048","article-title":"The role of immunosuppression in lymphoma formation","volume":"20","author":"Penn","year":"1998","journal-title":"Semin Immunopathol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB72","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.22056","article-title":"Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis","volume":"54","author":"Setoguchi","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB73","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-TNF therapy in RA and risk of malignant lymphomas: relative risks and time-trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB74","unstructured":"74.\u2002Amgen Inc. Enbrel Full Prescribing Information and Medication Guide. http:\/\/www.enbrel.com\/pdf\/enbrel_pi.pdf. Accessed February 2009."},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB75","unstructured":"75.\u2002Centocor Inc. Remicade Full Prescribing Information and Medication Guide. http:\/\/www.remicade.com\/remicade\/assets\/HCP_PPI.pdf. Accessed February 2009."},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB76","unstructured":"76.\u2002Abbott Laboratories. Humira Full Prescribing Information and Medication Guide. http:\/\/www.humirapro.com. Accessed February 2009."},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB77","unstructured":"77.\u2002US Food and Drug Administration. FDA Briefing Document. Update on the TNF blocking agents. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3930B1_01_B-TNF.Briefing.pdf. Accessed March 4, 2003."},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB78","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analysesof adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB79","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB80","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.296.18.2201-a","article-title":"Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis","volume":"296","author":"Costenbader","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB81","doi-asserted-by":"crossref","first-page":"2203-a-4","DOI":"10.1001\/jama.296.18.2203-b","article-title":"Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis-Reply","volume":"296","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB82","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/ard.2008.094904","article-title":"Etanercept therapy in rheumatoid arthritis and the risk of malignancies. A systematic review and individual patient data meta-analysis of randomised controlled trials","volume":"68","author":"Bongartz","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB83","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB84","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB85","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","article-title":"Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study","volume":"120","author":"Paul","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB86","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archderm.1997.03890430121016","article-title":"Lymphomas during long-term methotrexate therapy","volume":"133","author":"Kamel","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB87","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB88","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB89","first-page":"1705","article-title":"Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases","volume":"26","author":"Asten","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1529-8019.2009.01258.x-BIB90","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/ard.42.4.368","article-title":"The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up","volume":"42","author":"Baltus","year":"1983","journal-title":"Ann Rheum Dis"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1529-8019.2009.01258.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1529-8019.2009.01258.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:57:38Z","timestamp":1671818258000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1529-8019.2009.01258.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1529-8019.2009.01258.x","relation":{},"ISSN":["1396-0296","1529-8019"],"issn-type":[{"value":"1396-0296","type":"print"},{"value":"1529-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}